



## OPEN ACCESS

### Edited and reviewed by:

Théophile Godfraind, Université Catholique de Louvain, Belgium

#### \*Correspondence:

Frontiers Editorial Office editorial.office@frontiersin.org

#### Specialty section:

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

**Received:** 14 June 2017 **Accepted:** 14 June 2017 **Published:** 28 June 2017

#### Citation:

Frontiers Editorial Office (2017)
Expression of Concern: Topical
Ophthalmic Formulation of Trichostatin
A and SurR9-C84A for Quick
Recovery Post-alkali Burn of Corneal
Haze. Front. Pharmacol. 8:427.
doi: 10.3389/fphar.2017.00427

# Expression of Concern: Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze

Frontiers Editorial Office \*

An expression of concern on

Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze

by Roy, K., Cheung, C. H. A., Kanwar, R. K., Sandhir, R., and Kanwar, J. R. (2017). Front. Pharmacol. 8:223. doi: 10.3389/fphar.2017.00223

With this notice, Frontiers states its awareness of serious allegations surrounding the article "Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze" published on 5 May 2017. Our Chief Editors will direct an investigation in full accordance with our procedures. The situation will be updated as soon as the investigation is complete.

Copyright © 2017 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

1